Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Prostate Cancer | Review

The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target

Authors: Xuming Zhou, Keqiang Chai, Hezhen Zhu, Cong Luo, Xiaofeng Zou, Junrong Zou, Guoxi Zhang

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

The incidence of prostate cancer (PCa), the most prevalent malignancy, is currently at the forefront. RNA modification is a subfield of the booming field of epigenetics. To date, more than 170 types of RNA modifications have been described, and N6-methyladenosine (m6A) is the most abundant and well-characterized internal modification of mRNAs involved in various aspects of cancer progression. METTL3, the first identified key methyltransferase, regulates human mRNA and non-coding RNA expression in an m6A-dependent manner. This review elucidates the biological function and role of METTL3 in PCa and discusses the implications of METTL3 as a potential therapeutic target for future research directions and clinical applications.
Literature
1.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
3.
Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C. Global burden of urologic cancers, 1990-2013. Eur Urol. 2017;71(3):437–46.PubMedCrossRef
4.
Wong MC, Goggins WB, Wang HH, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70(5):862–74.PubMedCrossRef
5.
Gillessen S, Armstrong A, Attard G, et al. Management of patients with advanced prostate cancer: report from the advanced prostate cancer consensus conference 2021. Eur Urol. 2022;82(1):115–41.PubMedCrossRef
6.
7.
8.
9.
Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger rna from novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974;71(10):3971–5.PubMedPubMedCentralCrossRef
10.
11.
Ding Z, Liu Y, Huang Q, Cheng C, Song L, Zhang C, et al. M6a-and immune-related lncrna signature confers robust predictive power for immune efficacy in lung squamous cell carcinoma. View. 2023;4(3):20220083.CrossRef
12.
13.
14.
Geula S, Moshitch-Moshkovitz S, Dominissini D, et al. Stem cells. M6a mrna methylation facilitates resolution of naïve pluripotency toward differentiation. Science. 2015;347(6225):1002–6.PubMedCrossRef
15.
Horiuchi K, Kawamura T, Iwanari H, et al. Identification of wilms' tumor 1-associating protein complex and its role in alternative splicing and the cell cycle. J Biol Chem. 2013;288(46):33292–302.PubMedPubMedCentralCrossRef
16.
Schwartz S, Mumbach M, Jovanovic M, et al. Perturbation of m6a writers reveals two distinct classes of mrna methylation at internal and 5’ sites. Cell Rep. 2014;8(1):284–96.PubMedPubMedCentralCrossRef
17.
18.
Huang H, Weng H, Chen J. M(6)a modification in coding and non-coding rnas: roles and therapeutic implications in cancer. Cancer Cell. 2020;37(3):270–88.PubMedPubMedCentralCrossRef
19.
20.
21.
Xu C, Wang X, Liu K, et al. Structural basis for selective binding of m6a rna by the ythdc1 yth domain. Nat Chem Biol. 2014;10(11):927–9.PubMedCrossRef
22.
Li F, Zhao D, Wu J, Shi Y. Structure of the yth domain of human ythdf2 in complex with an m(6)a mononucleotide reveals an aromatic cage for m(6)a recognition. Cell Res. 2014;24(12):1490–2.PubMedPubMedCentralCrossRef
23.
24.
25.
Li T, Hu PS, Zuo Z, et al. Mettl3 facilitates tumor progression via an m(6)a-igf2bp2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019;18(1):112.PubMedPubMedCentralCrossRef
26.
27.
28.
29.
30.
31.
Li E, Wei B, Wang X, Kang R. Mettl3 enhances cell adhesion through stabilizing integrin β1 mrna via an m6a-hur-dependent mechanism in prostatic carcinoma. Am J Cancer Res. 2020;10:1012–25.PubMedPubMedCentral
32.
Boccaletto P, Stefaniak F, Ray A, et al. Modomics: a database of rna modification pathways. 2021 update. Nucleic Acids Res. 2022;50(d1):d231–5.PubMedCrossRef
33.
Barbieri I, Kouzarides T. Role of rna modifications in cancer. Nat Rev Cancer. 2020;20(6):303–22.PubMedCrossRef
34.
35.
36.
Davalos V, Blanco S, Esteller M. Snapshot: messenger rna modifications. Cell. 2018;174(2):498–498.e1.PubMedCrossRef
37.
38.
39.
Alarcón CR, Goodarzi H, Lee H, Liu X, Tavazoie S, Tavazoie SF. Hnrnpa2b1 is a mediator of m(6)a-dependent nuclear rna processing events. Cell. 2015;162(6):1299–308.PubMedPubMedCentralCrossRef
40.
41.
42.
43.
Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T. N(6)-methyladenosine-dependent rna structural switches regulate rna-protein interactions. Nature. 2015;518(7540):560–4.PubMedPubMedCentralCrossRef
44.
As W, Kretschmer J, Hackert P, et al. Human mettl16 is a n(6)-methyladenosine (m(6)a) methyltransferase that targets pre-mrnas and various non-coding rnas. EMBO Rep. 2017;18(11):2004–14.CrossRef
45.
46.
Niu Y, Zhao X, Wu YS, Li MM, Wang XJ, Yang YG. N6-methyl-adenosine (m6a) in rna: an old modification with a novel epigenetic function. Genom Proteom Bioinform. 2013;11(1):8–17.CrossRef
47.
48.
Chen Z, Zhong X, Xia M, Zhong J. The roles and mechanisms of the m6a reader protein ythdf1 in tumor biology and human diseases. Mol Ther Nucleic Acids. 2021;26:1270–9.PubMedPubMedCentralCrossRef
49.
50.
51.
52.
Knuckles P, Lence T, Haussmann IU, et al. Zc3h13/flacc is required for adenosine methylation by bridging the mrna-binding factor rbm15/spenito to the m(6)a machinery component wtap/fl(2)d. Genes Dev. 2018;32(5–6):415–29.PubMedPubMedCentralCrossRef
53.
Wen J, Lv R, Ma H, et al. Zc3h13 regulates nuclear rna m(6)a methylation and mouse embryonic stem cell self-renewal. Mol Cell. 2018;69(6):1028–1038.e6.PubMedPubMedCentralCrossRef
54.
Wei J, Liu F, Lu Z, et al. Differential m(6)a, m(6)a(m), and m(1)a demethylation mediated by fto in the cell nucleus and cytoplasm. Mol Cell. 2018;71(6):973–985.e5.PubMedPubMedCentralCrossRef
55.
Liu J, Jia G. Methylation modifications in eukaryotic messenger rna. J Genet Genomics. 2014;41(1):21–33.PubMedCrossRef
56.
Zou S, Toh JD, Wong KH, Gao YG, Hong W, Woon EC. N(6)-methyladenosine: a conformational marker that regulates the substrate specificity of human demethylases fto and alkbh5. Sci Rep. 2016;6:25677.PubMedPubMedCentralCrossRef
57.
58.
Cd A, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016;17(8):487–500.CrossRef
59.
Huang H, Weng H, Sun W, et al. Recognition of rna n(6)-methyladenosine by igf2bp proteins enhances mrna stability and translation. Nat Cell Biol. 2018;20(3):285–95.PubMedPubMedCentralCrossRef
60.
Liu N, Zhou KI, Parisien M, Dai Q, Diatchenko L, Pan T. N6-methyladenosine alters rna structure to regulate binding of a low-complexity protein. Nucleic Acids Res. 2017;45(10):6051–63.PubMedPubMedCentralCrossRef
61.
Petri BJ, Klinge CM. M6a readers, writers, erasers, and the m6a epitranscriptome in breast cancer. J Mol Endocrinol. 2023;70(2)
62.
Sun T, Wu R, Ming L. The role of m6a rna methylation in cancer. Biomed Pharmacother. 2019;112:108613.PubMedCrossRef
63.
64.
65.
Li Y, Su R, Deng X, Chen Y, Chen J. Fto in cancer: functions, molecular mechanisms, and therapeutic implications. Trends Cancer. 2022;8(7):598–614.PubMedCrossRef
66.
67.
Zaccara S, Ries Rj J Sr. Reading, writing and erasing mrna methylation. Nat Rev Mol Cell Biol. 2019;20(10):608–24.PubMedCrossRef
68.
69.
Wu R, Li A, Sun B, et al. A novel m(6)a reader prrc2a controls oligodendroglial specification and myelination. Cell Res. 2019;29(1):23–41.PubMedCrossRef
70.
Zhang F, Kang Y, Wang M, et al. Fragile x mental retardation protein modulates the stability of its m6a-marked messenger rna targets. Hum Mol Genet. 2018;27(22):3936–50.PubMedPubMedCentral
71.
72.
73.
Liao S, Sun H, Xu C. Yth domain: a family of n(6)-methyladenosine (m(6)a) readers. Genom Proteom Bioinform. 2018;16(2):99–107.CrossRef
74.
Patil DP, Pickering BF, Jaffrey SR. Reading m(6)a in the transcriptome: m(6)a-binding proteins. Trends Cell Biol. 2018;28(2):113–27.PubMedCrossRef
75.
Yang Y, Hsu PJ, Ys C, Yang YG. Dynamic transcriptomic m(6)a decoration: writers, erasers, readers and functions in rna metabolism. Cell Res. 2018;28(6):616–24.PubMedPubMedCentralCrossRef
76.
Peer E, Moshitch-Moshkovitz S, Rechavi G, Dominissini D. The epitranscriptome in translation regulation. Cold Spring Harb Perspect Biol. 2019;11(8)
77.
Livneh I, Moshitch-Moshkovitz S, Amariglio N, Rechavi G, Dominissini D. The m(6)a epitranscriptome: transcriptome plasticity in brain development and function. Nat Rev Neurosci. 2020;21(1):36–51.PubMedCrossRef
78.
79.
80.
81.
82.
83.
84.
85.
Luxton HJ, Simpson BS, Mills IG, Nr B, Ahmed Z, Stavrinides V, et al. The oncogene metadherin interacts with the known splicing proteins ythdc1, sam68 and t-star and plays a novel role in alternative mrna splicing. Cancers (basel). 2019;11 https://​doi.​org/​10.​3390/​cancers11091233.
86.
Song J, You G, Yin X, Zhu G, Wang W, Yu Y, et al. Overexpression of ythdc2 contributes to the progression of prostate cancer and predicts poor outcomes in patients with prostate cancer. J Biochem Mol Toxicol. 2023:e23308. https://​doi.​org/​10.​1002/​jbt.​23308.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
Śledź P, Jinek M. Structural insights into the molecular mechanism of the m(6)a writer complex. Elife. 2016;5
99.
Huang J, Dong X, Gong Z, et al. Solution structure of the rna recognition domain of mettl3-mettl14 n(6)-methyladenosine methyltransferase. Protein Cell. 2019;10(4):272–84.PubMedCrossRef
100.
Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol. 1999;292(2):195–202.PubMedCrossRef
101.
Ward JJ, Mcguffin LJ, Bryson K, Buxton BF, Jones DT. The disopred server for the prediction of protein disorder. Bioinformatics. 2004;20(13):2138–9.PubMedCrossRef
102.
Schöller E, Weichmann F, Treiber T, et al. Interactions, localization, and phosphorylation of the m(6)a generating mettl3-mettl14-wtap complex. RNA. 2018;24(4):499–512.PubMedPubMedCentralCrossRef
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
Yan R, Dai W, Wu R, Huang H, Shu M. Therapeutic targeting m6a-guided mir-146a-5p signaling contributes to the melittin-induced selective suppression of bladder cancer. Cancer Lett. 2022;534:215615.PubMedCrossRef
116.
Bi X, Lv X, Liu D, et al. Mettl3 promotes the initiation and metastasis of ovarian cancer by inhibiting ccng2 expression via promoting the maturation of pri-microrna-1246. Cell Death Discov. 2021;7(1):237.PubMedPubMedCentralCrossRef
117.
Jiang X, Yuan Y, Tang L, et al. Comprehensive pan-cancer analysis of the prognostic and immunological roles of the mettl3/lncrna-snhg1/mirna-140-3p/ube2c axis. Front Cell Dev Biol. 2021;9:765772.PubMedPubMedCentralCrossRef
118.
Ji F, Lu Y, Chen S, et al. M(6)a methyltransferase mettl3-mediated lncrna foxd2-as1 promotes the tumorigenesis of cervical cancer. Mol Ther Oncolytics. 2021;22:574–81.PubMedPubMedCentralCrossRef
119.
Xue L, Li J, Lin Y, et al. M(6) a transferase mettl3-induced lncrna abhd11-as1 promotes the Warburg effect of non-small-cell lung cancer. J Cell Physiol. 2021;236(4):2649–58.PubMedCrossRef
120.
Wang D, Wang X, Huang B, et al. Mettl3 promotes prostate cancer progression by regulating mir-182 maturation in m6a-dependent manner. Andrologia. 2022;54(7):1581–91.PubMedCrossRef
121.
Ma H, Zhang F, Zhong Q, Hou J. Mettl3-mediated m6a modification of kif3c-mrna promotes prostate cancer progression and is negatively regulated by mir-320d. Aging. 2021;13(18):22332–44.PubMedPubMedCentralCrossRef
122.
Mao Y, Li W, Weng Y, et al. Mettl3-mediated m(6)a modification of lncrna malat1 facilitates prostate cancer growth by activation of pi3k/akt signaling. Cell Transplant. 2022;31:9636897221122997.PubMedCrossRef
123.
Chen B, Liu C, Long H, Bai G, Zhu Y, Xu H. N(6)-methyladenosine-induced long non-coding rna pvt1 regulates the mir-27b-3p/blm axis to promote prostate cancer progression. Int J Oncol. 2023;62(1)
124.
125.
Qu S, Huang C, Zhu T, Wang K, Zhang H, Wang L, et al. Olfml3, as a potential predictor of prognosis and therapeutic target for glioma, is closely related to immune cell infiltration. View. 2023;4:20220052.CrossRef
126.
127.
128.
Wojtas MN, Pandey RR, Mendel M, Homolka D, Sachidanandam R, Pillai RS. Regulation of m6a transcripts by the 3’→5’ rna helicase ythdc2 is essential for a successful meiotic program in the mammalian germline. Mol Cell. 2017;68(2):374–387.e12.PubMedCrossRef
129.
Du H, Zhao Y, He J, et al. Ythdf2 destabilizes m(6)a-containing rna through direct recruitment of the ccr4-not deadenylase complex. Nat Commun. 2016;7:12626.PubMedPubMedCentralCrossRef
130.
Wang X, Lu Z, Gomez A, et al. N6-methyladenosine-dependent regulation of messenger rna stability. Nature. 2014;505(7481):117–20.PubMedCrossRef
131.
132.
Zhou J, Wan J, Gao X, Zhang X, Jaffrey SR, Qian SB. Dynamic m(6)a mrna methylation directs translational control of heat shock response. Nature. 2015;526(7574):591–4.PubMedPubMedCentralCrossRef
133.
134.
135.
136.
137.
Ma XX, Cao ZG, Zhao SL. M6a methyltransferase mettl3 promotes the progression of prostate cancer via m6a-modified lef1. Eur Rev Med Pharmacol Sci. 2020;24(7):3565–71.PubMed
138.
Babaei G, Aziz SG, Jaghi N. Emt, cancer stem cells and autophagy; the three main axes of metastasis. Biomed Pharmacother. 2021;133:110909.PubMedCrossRef
139.
140.
141.
Chen Y, Pan C, Wang X, et al. Silencing of mettl3 effectively hinders invasion and metastasis of prostate cancer cells. Theranostics. 2021;11(16):7640–57.PubMedPubMedCentralCrossRef
142.
Liang L, Li Q, Huang LY, et al. Loss of arhgdia expression is associated with poor prognosis in hcc and promotes invasion and metastasis of hcc cells. Int J Oncol. 2014;45(2):659–66.PubMedCrossRef
143.
144.
Klaassen Z, Howard LE, De Hoedt A, et al. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer. 2017;123(9):1528–35.PubMedCrossRef
145.
146.
Carvalho TM, Cardoso HJ, Figueira MI, Vaz CV, Socorro S. The peculiarities of cancer cell metabolism: a route to metastasization and a target for therapy. Eur J Med Chem. 2019;171:343–63.PubMedCrossRef
147.
Sadeghi RN, Karami-Tehrani F, Salami S. Targeting prostate cancer cell metabolism: impact of hexokinase and cpt-1 enzymes. Tumour Biol. 2015;36(4):2893–905.PubMedCrossRef
148.
149.
Liu J, Yuan JF, Wang YZ. Mettl3-stabilized lncrna snhg7 accelerates glycolysis in prostate cancer via srsf1/c-myc axis. Exp Cell Res. 2022;416(1):113149.PubMedCrossRef
150.
151.
Lin Y, Wei X, Jian Z, Zhang X. Mettl3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma. Cancer Med. 2020;9(8):2859–67.PubMedPubMedCentralCrossRef
152.
Wang Y, Chen J, Wu Z, et al. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021;178(2):239–61.PubMedCrossRef
153.
154.
Cotter KA, Gallon J, Uebersax N, et al. Mapping of m(6)a and its regulatory targets in prostate cancer reveals a mettl3-low induction of therapy resistance. Mol Cancer Res. 2021;19(8):1398–411.PubMedPubMedCentralCrossRef
155.
Boriack-Sjodin PA, Ribich S, Copeland RA. Rna-modifying proteins as anticancer drug targets. Nat Rev Drug Discov. 2018;17(6):435–53.PubMedCrossRef
156.
Bedi RK, Huang D, Eberle SA, Wiedmer L, Śledź P, Caflisch A. Small-molecule inhibitors of mettl3, the major human epitranscriptomic writer. Chemmedchem. 2020;15(9):744–8.PubMedCrossRef
157.
Moroz-Omori EV, Huang D, Kumar Bedi R, et al. Mettl3 inhibitors for epitranscriptomic modulation of cellular processes. Chemmedchem. 2021;16(19):3035–43.PubMedPubMedCentralCrossRef
158.
Dolbois A, Bedi RK, Bochenkova E, et al. 1,4,9-triazaspiro[5.5]undecan-2-one derivatives as potent and selective mettl3 inhibitors. J Med Chem. 2021;64(17):12738–60.PubMedCrossRef
159.
Yankova E, Blackaby W, Albertella M, et al. Small-molecule inhibition of mettl3 as a strategy against myeloid leukaemia. Nature. 2021;593(7860):597–601.PubMedPubMedCentralCrossRef
160.
Ofir-Rosenfeld Y, Vasiliauskaitė L, Saunders C, et al. Stc-15, an oral small molecule inhibitor of the rna methyltransferase mettl3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling, and synergises with t cell checkpoint blockade. Eur J Cancer. 2022;174:s123.CrossRef
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
174.
Ni Z, Sun P, Zheng J, et al. Jnk signaling promotes bladder cancer immune escape by regulating mettl3-mediated m6a modification of pd-l1 mrna. Cancer Res. 2022;82(9):1789–802.PubMedCrossRef
175.
Song C, Zhou C. Hoxa10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of tgfb2/smad/mettl3 signaling axis. J Exp Clin Cancer Res. 2021;40(1):62.PubMedPubMedCentralCrossRef
176.
Meng W, Xiao H, Mei P, et al. Critical roles of mettl3 in translation regulation of cancer. Biomolecules. 2023;13(2)
177.
178.
Chamorro-Jorganes A, Sweaad WK, Katare R, et al. Mettl3 regulates angiogenesis by modulating let-7e-5p and mirna-18a-5p expression in endothelial cells. Arterioscler Thromb Vasc Biol. 2021;41(6):e325–37.PubMedCrossRef
179.
Zhang G, Wang T, Huang Z, et al. Mettl3 dual regulation of the stability of linc00662 and vegfa rnas promotes colorectal cancer angiogenesis. Discov Oncol. 2022;13(1):89.PubMedPubMedCentralCrossRef
180.
Wang G, Dai Y, Li K, et al. Deficiency of mettl3 in bladder cancer stem cells inhibits bladder cancer progression and angiogenesis. Front Cell Dev Biol. 2021;9:627706.PubMedPubMedCentralCrossRef
181.
182.
183.
Gao Q, Zheng J, Ni Z, et al. The m(6)a methylation-regulated aff4 promotes self-renewal of bladder cancer stem cells. Stem Cells Int. 2020;2020:8849218.PubMedPubMedCentralCrossRef
184.
Zhang C, Samanta D, Lu H, et al. Hypoxia induces the breast cancer stem cell phenotype by hif-dependent and alkbh5-mediated m6a-demethylation of nanog mrna. Proc Natl Acad Sci U S A. 2016;113(14):e2047–56.PubMedPubMedCentralCrossRef
185.
186.
Lothion-Roy J, Haigh DB, Harris AE, et al. Clinical and molecular significance of the rna m(6)a methyltransferase complex in prostate cancer. Front Genet. 2022;13:1096071.PubMedCrossRef
187.
Cai C, He HH, Chen S, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011;20(4):457–71.PubMedPubMedCentralCrossRef
188.
Kashyap V, Ahmad S, Nilsson EM, et al. The lysine specific demethylase-1 (lsd1/kdm1a) regulates vegf-a expression in prostate cancer. Mol Oncol. 2013;7(3):555–66.PubMedPubMedCentralCrossRef
189.
Cai C, He HH, Gao S, et al. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep. 2014;9(5):1618–27.PubMedPubMedCentralCrossRef
190.
Lence T, Akhtar J, Bayer M, et al. M(6)a modulates neuronal functions and sex determination in drosophila. Nature. 2016;540(7632):242–7.PubMedCrossRef
191.
Haussmann IU, Bodi Z, Sanchez-Moran E, et al. M(6)a potentiates sxl alternative pre-mrna splicing for robust drosophila sex determination. Nature. 2016;540(7632):301–4.PubMedCrossRef
192.
193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
204.
205.
Metadata
Title
The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target
Authors
Xuming Zhou
Keqiang Chai
Hezhen Zhu
Cong Luo
Xiaofeng Zou
Junrong Zou
Guoxi Zhang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11741-1

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Association between psychiatric disorders and glioma risk: evidence from Mendelian randomization analysis

Research

Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer

Research

Development of a nomogram for prediction of central lymph node metastasis of papillary thyroid microcarcinoma

Research

CLEC19A overexpression inhibits tumor cell proliferation/migration and promotes apoptosis concomitant suppression of PI3K/AKT/NF-κB signaling pathway in glioblastoma multiforme

Research

Exosomes derived from cancer-associated fibroblasts promote tumorigenesis, metastasis and chemoresistance of colorectal cancer by upregulating circ_0067557 to target Lin28

Research

ESCO2’s oncogenic role in human tumors: a pan-cancer analysis and experimental validation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits